OmniAb, Inc. Stock Price, News & Analysis

OmniAb (NASDAQ: OABI) reported Q1 2025 financial results with revenue of $4.2 million, up from $3.8 million in Q1 2024. The company posted a net loss of $18.2 million ($0.17 per share), compared to $19.0 million loss in Q1 2024. Key highlights include: three new platform license agreements, 95 active partners, and 378 active programs. The company affirmed 2025 revenue guidance of $20-25 million and revised operating expenses to $85-90 million. Notable developments include a $3 million upfront payment from Angelini Pharma deal with potential milestones over $170 million, and the launch of xPloration® Partner Access Program. Partner updates include positive clinical results for Immunovant's IMVT-1402 and batoclimab programs, and CStone's EMA submission for sugemalimab in NSCLC treatment.

OmniAb (NASDAQ: OABI) has launched the xPloration Partner Access Program, allowing current partners to purchase their proprietary high-throughput single B-cell screening platform. The xPloration instrument leverages machine learning and AI to enhance antibody discovery and development capabilities.

The platform features custom chips with 1.5 million microcapillaries for B-cell isolation and completes instrument runs in approximately 1.5 hours. Key advantages include superior processing speed, exceptional hit recovery, and enhanced discovery efficiency through laser-based recovery and advanced functional screening assays. The technology will be showcased at the 21st Annual PEGS Boston Summit (May 12-16, 2025) through presentations by Dr. Bob Chen and Dr. John Kenney.

OmniAb (NASDAQ: OABI) has announced its participation in five upcoming investor conferences in May and June 2025. The company's management will attend:

• H.C. Wainwright 1st Annual Royalty Company Virtual Conference (May 13)
• H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (May 20)
• RBC Capital Markets Global Healthcare Conference (May 20-21)
• Benchmark 2025 Healthcare House Call Virtual Conference (May 29)
• Jefferies Global Healthcare Conference (June 3-5)

Management will participate in fireside chats, panel discussions, and one-on-one meetings with investors across these events.

OmniAb (NASDAQ: OABI) has announced two strategic appointments to its Board of Directors: Philip J. Gotwals, Ph.D., and Steve Crouse, while Director Sarah Boyce steps down after nearly six years of service. These changes increase the board size to seven members.

Dr. Gotwals brings 30 years of biopharmaceutical experience, notably as Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research, where his team executed over 50 major strategic transactions. He will serve on the Human Capital Management & Compensation Committee and Science & Technology Committee.

Steve Crouse, currently Senior Vice President and General Manager of Bio-Techne's Analytical Solutions Division, contributes over 20 years of life sciences expertise. He will serve on the Audit Committee and Science & Technology Committee.

OmniAb (NASDAQ: OABI) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after U.S. financial markets close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the quarterly results and provide business updates.

Participants can join via phone using U.S. number (800) 549 8228 or International number (289) 819 1520 with Conference ID 96760. A live webcast with slides will also be available.

OmniAb (NASDAQ: OABI) reported its Q4 and full-year 2024 financial results. Q4 revenue increased to $10.8 million from $4.8 million in Q3 2023, while full-year 2024 revenue decreased to $26.4 million from $34.2 million in 2023. The company reported a Q4 net loss of $13.1 million ($0.12 per share) and a full-year net loss of $62.0 million ($0.61 per share).

As of December 31, 2024, OmniAb had 91 active partners and 363 active programs, including 32 OmniAb-derived programs in clinical development or commercialization. The company signed 10 new license agreements in 2024. For 2025, OmniAb projects revenue between $20-25 million and operating expenses of $90-95 million.

The company launched OmniHub™, a unified interface for partners to access discovery campaign data. Notable partner developments include Immunovant's IMVT-1402 progress, with six IND applications cleared, and various clinical advancements in partner programs including batoclimab, acasunlimab, and sugemalimab.

OmniAb (NASDAQ: OABI) will announce its fourth quarter and full-year 2024 financial results on March 18, 2025, after the U.S. financial markets close. The company will also hold a conference call on the same day at 4:30 p.m. Eastern time to discuss the results.

OmniAb (NASDAQ: OABI) has announced its participation in two major investor conferences in March. The company will attend the TD Cowen 45th Annual Health Care Conference from March 3-5 at the Boston Marriott Copley Place, where management will deliver a corporate overview on March 4th at 2:30 p.m. Eastern time and conduct one-on-one investor meetings.

Additionally, OmniAb will participate in the 2025 Leerink Partners Global Healthcare Conference from March 9-12 at the W Hotel South Beach in Miami, with management scheduled for one-on-one investor meetings on March 12th.

OmniAb (NASDAQ: OABI) presented two key technologies at the 2024 Antibody Engineering & Therapeutics Conference in San Diego. The first presentation showcased the company's workflow for building multispecifics, including CD3 T cell and NK cell engagers, highlighting their naturally optimized human sequence immune repertoires and AI-augmented single B cell workflows. The second presentation introduced OmniHub™, a high-dimensional unified bioinformatics portal designed to enhance partner experience through scalable data transfer, advanced visualization, and comprehensive tool access.

The company demonstrated how they discovered developable anti-NKp46 binders with broad epitope coverage, utilizing high-throughput phenotypic screening enhanced with AI-guided next-generation sequencing workflow to identify high-quality leads without extensive ex vivo engineering.